Tag: Skolkovo

Nuclear Medicine Center, Biotech Laboratory to be Set Up in Skolkovo Medical Cluster

skolkovo
Skolkovo Foundation concluded six agreements to facilitate medical, educational and research projects in healthcare at the St. Petersburg international economic forum. A versatile full-cycle biotec...

Skolkovo resident company printed live tissue in space

3d printing
Skolkovo resident company 3D Bioprinting Solutions has become the first company to use a 3D printer to create live tissue in space, printing an organ construct for the thyroid gland of a mouse.

Five Russian startups present their projects at Cambridge Biomedical Campus

astrazeneca-cambridge
The winners of the Startup Challenge accelerator, organised jointly by the Skolkovo Foundation and AstraZeneca, are showcasing their inventions at the International Future Healthcare Forum.

Skolkovo resident Brain Beat receives the prize at Asian Entrepreneurship Award

blood-sugar
Brain Beat, a resident company of the Skolkovo Foundation’s biomed cluster that has developed a non-invasive glucometer, won second prize at the 7th Asian Entrepreneurship Award in Japan.

Bayer rewards Skolkovo’s innovation biomedicine projects

skolkovo
Three innovative biomed projects were selected as the winners of the Patents Power competition last week organised by the Skolkovo Foundation, the pharmaceutical giant Bayer and Rospatent.

The fifth Pharma’s Cool educational programme began at Skolkovo Technopark

skolkovo
Pharma’s Cool aims to teach students and startups about the practical aspects of drug development and getting a new drug to the market.

Bayer and Skolkovo set up a competition for biotech startups

skolkovo
The Skolkovo has teamed up with Bayer to launch a competition to help biotech startups advance their projects and secure their intellectual property rights.

The top five Russian biotech startups are Skolkovo residents

skolkovo
Rusbase published a list of the top five most interesting biotech startups in Russia, and all are residents of the Skolkovo Foundation.

Genetico was accredited by SKOLKOVO Foundation as a Common Use Center

genetico
Genetico will provide services for genome sequencing, analysis of single cells and their specific activity, and chromosomal microarray analysis to the residents of Biomed Cluster.

Russian scientists developed a combined cancer drug

research
Gene Surgery, a resident of SKOLKOVO, has conducted preclinical study of AntioncoRAN-M, an original cancer drug developed in Russia.

AstraZeneca and Skoltech signed a memorandum on HR development cooperation

skolkovo
AstraZeneca and Skolkovo Institute of Science and Technology announced the signing of a memorandum of intent for improving the professional competencies in the pharmaceutical industry.

First Russian intradermal implant obtained registration

pharma
The first Russian intradermal implant has successfully passed the state registration. This product has been developed over the past three years with the support of the Russian Ministry of Industry and Trade.

AstraZeneca and SKOLKOVO launched Startup Challenge 2018 acceleration program

skolkovo-astrazeneca
AstraZeneca and SKOLKOVO Foundation announced the launch of a joint acceleration program for projects in the area of oncology, cardiovascular, metabolic, kidney, respiratory, and autoimmune diseases.

Ruspharmtech has received U.S. patent for cancer drug alofanib

research
Russian Pharmaceutical Technologies (Ruspharmtech, a SKOLKOVO resident) has increased the commercial value of its patent portfolio by obtaining a US patent.

BioNeuroPharma starts collaboration with Cuban Neuroscience Center

pharm
BioNeuroPharma, a participant of SKOLKOVO biomed cluster, reached an agreement with the Cuban Neuroscience Center (CNEURO) on collaboration in the development of potential drugs for treatment of Alzheimer's disease.

New Skoltech supercomputer will improve the effectiveness of drug development

research
The upgrade will increase the peak performance of Skoltech’s supercomputer infrastructure by an order of magnitude, and this will open some qualitatively new opportunities